




**Ben Albritton**  
*President of the Senate*

## THE FLORIDA LEGISLATURE



**Daniel Perez**  
*Speaker of the House of  
Representatives*

June 13, 2025

The Honorable Ben Albritton  
President of the Senate

The Honorable Daniel Perez  
Speaker, House of Representatives

Dear Mr. President and Mr. Speaker:

Your Conference Committee on the disagreeing votes of the two houses on HB 5015, same being:

An act relating to State Group Insurance.

having met, and after full and free conference, do recommend to their respective houses as follows:

1. That the Senate recede from its Amendment 943470.
2. That the Senate and House of Representatives adopt the Conference Committee Amendment attached hereto, and by reference made a part of this report.

<i>Senator Ed Hooper, Chair</i>	<i>Senator Kristen Aston Arrington</i>
<i>Senator Bryan Avila</i>	<i>Senator Lori Berman, At Large</i>
<i>Senator Mack Bernard</i>	<i>Senator Jim Boyd, At Large</i>
<i>Senator Jennifer Bradley</i>	<i>Senator Jason Brodeur, At Large</i>
<i>Senator Danny Burgess</i>	<i>Senator Colleen Burton</i>
<i>Senator Alexis Calatayud</i>	<i>Senator Jay Collins</i>
<i>Senator Tracie Davis</i>	<i>Senator Nick DiCeglie</i>
<i>Senator Don Gaetz</i>	<i>Senator Ileana Garcia</i>
<i>Senator Erin Grall</i>	<i>Senator Joe Gruters, At Large</i>
<i>Senator Gayle Harrell</i>	<i>Senator Blaise Ingolia</i>
<i>Senator Shevrin D. Jones</i>	<i>Senator Thomas J. Leek</i>
<i>Senator Jonathan Martin</i>	<i>Senator Stan McClain</i>
<i>Senator Rosalind Osgood</i>	<i>Senator Kathleen Passidomo, At Large</i>
<i>Senator Jason W. B. Pizzo</i>	<i>Senator Tina Scott Polsky</i>
<i>Senator Ana Maria Rodriguez</i>	<i>Senator Darryl Ervin Rouson, At Large</i>
<i>Senator Barbara Sharief</i>	<i>Senator Corey Simon</i>
<i>Senator Carlos Guillermo Smith</i>	<i>Senator Keith L. Truenow</i>
<i>Senator Jay Trumbull</i>	<i>Senator Tom A. Wright</i>
<i>Senator Clay Yarborough</i>	

**Conferees on the part of the Senate**

<i>Representative Lawrence McClure, Chair</i>	<i>Representative Robert Charles Brannan III, At Large</i>
<i>Representative James Buchanan, At Large</i>	<i>Representative Jennifer Canady, At Large</i>
<i>Representative Joe Casello, At Large</i>	<i>Representative Kevin D. Chambliss, At Large</i>
<i>Representative Fentrice Driskell, At Large</i>	<i>Representative Wyman Duggan, At Large</i>
<i>Representative Anna V. Eskamani, At Large</i>	<i>Representative Sam Garrison, At Large</i>
<i>Representative Christine Hunschofsky, At Large</i>	<i>Representative Traci Koster, At Large</i>
<i>Representative Lauren Melo, At Large</i>	<i>Representative James Vernon Mooney, Jr., At Large</i>
<i>Representative Tobin Rogers Overdorf, At Large</i>	<i>Representative Michele K. Rayner, At Large</i>
<i>Representative Felicia Simone Robinson, At Large</i>	<i>Representative William Cloud Robinson, At Large</i>
<i>Representative Tyler I. Sirois, At Large</i>	<i>Representative Allison Tant, At Large</i>
<i>Representative Josie Tomkow, At Large</i>	<i>Representative Kaylee Tuck, At Large</i>
<i>Representative Susan L. Valdés, At Large</i>	<i>Representative Marie Paule Woodson, At Large</i>

**Managers on the part of the House of Representatives**

June 13, 2025

The Conference Committee Amendment for HB 5015, relating to State Group Insurance Program, amends provisions related to implementation of formulary management for prescription drugs and supplies under the State Employees' Prescription Drug Program.

The amendment requires the Department of Management Services (DMS) to submit recommendations to the Governor and the Legislative Budget Commission (LBC) by September 1, 2025, on the implementation of formulary management for prescription drugs and supplies for the 2026 plan year. The recommendations must relate to:

- Lists of excluded prescription drugs and supplies for a recommended formulary, with a comparison to the formulary in effect during the 2025 plan year. A recommended formulary is not required to authorize drugs to be made available for inclusion if a physician, advanced practice registered nurse, or physician assistant prescribing a pharmaceutical clearly states on the prescription that the excluded drug is medically necessary.
- Lists of included prescription drugs and supplies for a recommended formulary, with a comparison to the formulary in effect during the 2025 plan year.
- Prior authorization of specified prescription drugs and supplies.
- Step therapy of specified prescription drugs and supplies.

The DMS is required to submit supporting information for its recommendations: relevant information identifying the prescription drugs and supplies affected, the number of plan members and prescriptions affected for each identified drug or supply, and the cost savings expected for each recommended component implemented.

The amendment prohibits prescription drugs and supplies first made available in the marketplace after January 1, 2026, from being covered by the prescription drug program until specifically included in the list of covered prescription drugs and supplies.

The LBC may consider the recommendations of the DMS in total or in part, and, beginning in the 2026 plan year, the DMS may only implement the recommendations approved by the LBC.

Effective January 1, 2026, and only if the LBC approves one or more of the recommendations of the DMS related to lists of excluded prescription drugs and supplies for a recommended formulary, the amendment repeals the requirement for drugs excluded from the formulary to be available for inclusion if a physician, advanced practice registered nurse, or physician assistant prescribing a pharmaceutical clearly states on the prescription that the excluded drug is medically necessary. Additionally, the directive to the DMS to make the recommendations to the LBC is repealed. If the LBC approves one or more of the recommendations of the DMS related to lists of excluded prescription drugs and supplies for a recommended formulary, it must notify the Division of Law Revision of such approval.

The amendment requires the DMS to submit on an annual basis the list of prescription drugs and supplies that will be excluded from program coverage during the next plan year. This list must be submitted by September 1 each year, instead of October 1 as provided under current law. Further, the list must include, for informational purposes only, the list of prescription drugs and supplies that are recommended to be subject to a higher copayment for the next plan year. Any prescription drugs and supplies that will be excluded from program coverage, whether on the list

submitted or as proposed by the DMS during the plan year, must be must be approved by the Legislative Budget Commission (LBC).